Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine

•Developing a novel tumor vaccine delivery strategy through a biodegradable microneedle patch (MN), which allows sustained release of tumor antigen and induces long term anti-tumor response.•A tumor antigen peptide (OVA257–264: SIINFEKL) was fused with hepatitis b core (HBc) protein virus like parti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied materials today 2021-09, Vol.24, p.101110, Article 101110
Hauptverfasser: Guo, Qiuyan, Wang, Chufan, Zhang, Qiang, Cheng, Keman, Shan, Wenjun, Wang, Xiumin, Yang, Jun, Wang, Yunlong, Ren, Lei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Developing a novel tumor vaccine delivery strategy through a biodegradable microneedle patch (MN), which allows sustained release of tumor antigen and induces long term anti-tumor response.•A tumor antigen peptide (OVA257–264: SIINFEKL) was fused with hepatitis b core (HBc) protein virus like particles (OVA-HBc VLPs) to increase the immunogenicity of tumor antigen.•Mesoporous silica nanoparticles (MSN) were adopted as a vaccine adjuvant for enhancing the function of dendritic cells (DCs).•CpG-DNA were used to enhance the therapeutic effect of MSN/OVA-HBc@MN in distant tumors and long term immune memory effect. Tumor vaccines have made a significant breakthrough in clinical trials of cancer therapy, but have shown limited efficacy. Herein, we develop a novel tumor vaccine delivery strategy through a biodegradable microneedle patch (MN), which allows sustained release of tumor antigen and induces long term anti-tumor response. A tumor antigen peptide (OVA257–264: SIINFEKL) was fused with hepatitis B core (HBc) protein virus like particles (OVA-HBc VLPs) to increase the immunogenicity of tumor antigen. Mesoporous silica nanoparticles (MSN) were adopted as a vaccine adjuvant for enhancing the function of dendritic cells (DCs). OVA-HBc VLPs and MSN were capsulated into microneedles together [MSN/OVA-HBc@MN]. MSN/OVA-HBc@MN could significantly stimulate DC maturation and increase the presentation of OVA on DCs in vitro. MSN/OVA-HBc@MN can effectively stimulate antigen specific anti-tumor immune response and be used as prophylactic vaccines to effectively inhibit tumor formation. Moreover, the addition of CpG-DNA can enhance the therapeutic effect of MSN/OVA-HBc@MN in distant tumors and long term immune memory effect. Our results thus demonstrate that MSN-CpG/OVA-HBc@MN could be as a potential tumor-specific vaccination platform for tumor therapy. [Display omitted] A tumor vaccine patch, that loaded with OVA-HBc, CpG and MSN, was designed for preventing tumor formation and killing existed tumor.
ISSN:2352-9407
DOI:10.1016/j.apmt.2021.101110